Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guidant (GDT) -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (154)	1/10/2000 10:42:00 PM
From: Silver Knife	Respond to of 235

Guidant sees rising share of stent market Monday January 10, 8:37 pm Eastern Time SAN FRANCISCO, Jan 10 (Reuters) - Medical device maker Guidant Corp. (NYSE:GDT - news) expects its share of the market for stents used in angioplasty to rise this year following the launch of its Tristar stent late last year, the company's chief executive officer said on Monday. ``We had about a 50 percent market share in December and the launch was just in the last week of the year,' CEO Ronald Dollens said at a biotechnology conference here. Guidant, based in Indianapolis, also expects to launch its new implantable defibrillator, the Prizm, later this month, pending final U.S. Food and Drug Administration approval, he said. Dollens said the company expects to launch its Tetra stent in the United States by the fourth quarter and by mid-year in Europe. ``In 2000, we expect growth in the mid- to high-teens even with more aggressive price competition than we saw last year,' Dollens said of the stent market. He projected that defibrillators will be used in a greater percentage of patients with congestive heart failure due to their proven ability to save lives. Dollens noted that Guidant has 1,350 issued or pending patents, 26 of which are currently under litigation. He said a court case with Boston Scientific Corp. (NYSE:BSX - news) would likely be decided in March.